CITATION REPORT List of articles citing



DOI: 10.1007/s00280-019-03860-z Cancer Chemotherapy and Pharmacology, 2019, 84, 15-32.

Source: https://exaly.com/paper-pdf/73214091/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients. <i>Ophthalmic Research</i> , 2020 , 63, 358-368	2.9	7
31	Construction of immune-related risk signature for uveal melanoma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2020 , 48, 912-919	6.1	2
30	Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920917566	5.4	4
29	Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. <i>Pharmaceutics</i> , 2020 , 12,	6.4	40
28	Diabetic Retinopathy and Ocular Melanoma: How Far We Are?. <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 2777	2.6	1
27	Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 555-569	5.9	1
26	The Role of LncRNAs in Uveal Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	4
25	Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma. <i>Ophthalmic Genetics</i> , 2021 , 42, 732-743	1.2	1
24	Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. <i>Future Oncology</i> , 2021 , 17, 4583-4606	3.6	1
23	A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
22	Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018. <i>International Journal of General Medicine</i> , 2021 , 14, 4171-4176	2.3	1
21	Identification of Versican as an Independent Prognostic Factor in Uveal Melanoma. <i>International Journal of General Medicine</i> , 2021 , 14, 4639-4651	2.3	O
20	The Trends of Uveal Melanoma Research in the Past Two Decades and Future Perspectives. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 1-10	2.7	
19	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. <i>Biomedicines</i> , 2021 , 9,	4.8	6
18	LncRNA Acts as an Oncogene in Uveal Melanoma by Regulating an RNA-Based Network. <i>Cancers</i> , 2020 , 12,	6.6	20
17	ANALYSIS OF METASTASIS-FREE SURVIVAL IN PATIENTS WITH SMALL CHOROID MELANOMA DEPENDING ON THE TYPE OF PRIMARY TUMOR TREATMENT. <i>Siberian Journal of Oncology</i> , 2021 , 20, 108-114	0.3	
16	Changes in microRNA expression associated with metastasis and survival in patients with uveal melanoma. <i>Oncotarget</i> , 2020 , 11, 1435-1447	3.3	3

CITATION REPORT

15	Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures. <i>Scientific Reports</i> , 2021 , 11, 22244	4.9	1
14	The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas. <i>Cancers</i> , 2021 , 13,	6.6	
13	Construction and Validation of a Novel Pyroptosis-Related Gene Signature to Predict the Prognosis of Uveal Melanoma <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 761350	5.7	6
12	Histopathologic and MR Imaging Appearance of Spontaneous and Radiation-Induced Necrosis in Uveal Melanomas: Initial Results <i>Cancers</i> , 2022 , 14,	6.6	O
11	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma <i>Cancers</i> , 2022 , 14,	6.6	О
10	Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	O
9	Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?. <i>Cancers</i> , 2021 , 13,	6.6	O
8	Imaging of Uveal Melanomalurrent Standard and Methods in Development. <i>Cancers</i> , 2022 , 14, 3147	6.6	2
7	Selected Flavonoids to Target Melanoma: A Perspective in Nanoengineering Delivery Systems. <i>Bioengineering</i> , 2022 , 9, 290	5.3	
6	Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.		O
5	Identification of Immune-Related lncRNAs for Predicting Prognosis and Immune Landscape Characteristics of Uveal Melanoma. 2022 , 2022, 1-12		0
4	Identification of 5 microRNA biomarkers associated with the prognosis of uveal melanoma. 2022 , 101, e30366		1
3	Ocular Complications of Radiotherapy in Uveal Melanoma. 2023 , 15, 333		О
2	Multiple epigenetic modification profiles reveal the tumor immune microenvironment and clinical outcomes of uveal melanoma. 14,		O
1	RUVBL1-modulated chromatin remodeling alters the transcriptional activity of oncogenic CTNNB1 in uveal melanoma. 2023 , 9,		0